Crescita Free Cash Flow Yield from 2010 to 2026

CTX Stock  CAD 0.47  0.02  4.08%   
Crescita Therapeutics Free Cash Flow Yield yearly trend continues to be very stable with very little volatility. Free Cash Flow Yield is likely to grow to 0.13 this year. Free Cash Flow Yield is a financial solvency ratio that compares the free cash flow per share Crescita Therapeutics is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share. View All Fundamentals
 
Free Cash Flow Yield  
First Reported
2010-12-31
Previous Quarter
0.12
Current Value
0.13
Quarterly Volatility
0.50202432
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.
Evaluating Crescita Therapeutics's Free Cash Flow Yield across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.

Latest Crescita Therapeutics' Free Cash Flow Yield Growth Pattern

Below is the plot of the Free Cash Flow Yield of Crescita Therapeutics over the last few years. It is a financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share. Crescita Therapeutics' Free Cash Flow Yield historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Yield10 Years Trend
Slightly volatile
   Free Cash Flow Yield   
       Timeline  

Crescita Free Cash Flow Yield Regression Statistics

Arithmetic Mean(0.32)
Coefficient Of Variation(157.04)
Mean Deviation0.43
Median(0.18)
Standard Deviation0.50
Sample Variance0.25
Range1.7345
R-Value0.70
Mean Square Error0.14
R-Squared0.49
Significance0
Slope0.07
Total Sum of Squares4.03

Crescita Free Cash Flow Yield History

2026 0.13
2025 0.12
2024 0.14
2023 0.2
2022 -0.0915
2021 -0.14
2020 0.38

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as Free Cash Flow Yield, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Free Cash Flow Yield 0.12  0.13 

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.